9 Meters Biopharma, Inc.

[Company Presentations]

9 Meters Biopharma is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor.  The Company is advancing vurolenatide, a proprietary long-acting GLP-1 agonist for short bowel syndrome (SBS) and a number of near clinical-stage assets including NM-136, a humanized anti-GIP monoclonal antibody for obesity disorders.

Ticker:
NMTR
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Gastrointestinal
Lead Product in Development:
Vurolenatide for short bowel syndrome
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President & CEO
9 Meters Biopharma, Inc.